Tumor Markers in Germ Cell Tumors

Mandatory Marker Panel

• The European Society for Medical Oncology recommends that AFP and β-HCG must be measured before any intervention in patients with suspected germ cell tumors for diagnosis, risk stratification, treatment monitoring, and surveillance, while LDH serves as a critical prognostic factor in advanced disease 1, 2.
• The National Comprehensive Cancer Network suggests that for both seminoma and non-seminoma, AFP and β-HCG must be measured before any intervention, and in advanced disease, LDH must be added to this panel as it functions as an independent prognostic factor 1, 2, 3, 4.

Diagnostic Role

• Elevated AFP or β-HCG supports the diagnosis of germ cell cancer in young men with retroperitoneal, supraclavicular, or mediastinal masses, according to the European Society for Medical Oncology 1, 2, 3, 4.
• In rare patients with life-threatening metastatic disease and unequivocally elevated AFP or β-HCG, substantially elevated markers may be considered sufficient for diagnosis, and chemotherapy should not be delayed for tissue diagnosis, as recommended by the American Society of Clinical Oncology 5, 6.

Risk Stratification Using IGCCCG Classification

• The International Germ Cell Cancer Collaborative Group uses marker thresholds to stratify patients into prognostic groups that determine treatment intensity, with the following categories: S1 (Good prognosis): LDH <1.5× ULN, β-HCG <5,000 IU/L, AFP <1,000 ng/mL, S2 (Intermediate prognosis): LDH 1.5-10× ULN, β-HCG 5,000-50,000 IU/L, AFP 1,000-10,000 ng/mL, and S3 (Poor prognosis): LDH >10× ULN, β-HCG >50,000 IU/L, or AFP >10,000 ng/mL, as defined by the National Comprehensive Cancer Network 7.

Treatment Monitoring

• The American Society of Clinical Oncology recommends measuring AFP, β-HCG, and LDH before each chemotherapy cycle to assess treatment response, with the half-life kinetics during chemotherapy indicating treatment effectiveness 5, 6.
• If tumor marker levels rise between day 1 of cycle 1 and day 1 of cycle 2, repeat assays midway through cycle 2 to determine whether levels have begun to decline, as suggested by the European Society for Medical Oncology 5.

Critical Interpretation Pitfalls

• Hypogonadism from orchiectomy and chemotherapy can cause false β-HCG elevation; supplemental testosterone can reduce this, according to the American Society of Clinical Oncology 7.
• Heterophilic antibodies can cause false-positive hCG results, particularly in women, as noted by the National Comprehensive Cancer Network 5, 7, 8.
• Liver dysfunction from chemotherapy, anesthetics, antiepileptics, viral hepatitis, or alcohol can elevate AFP without tumor progression, and must be interpreted with caution to avoid unnecessary treatments, as recommended by the European Society for Medical Oncology 7.

Surveillance After Treatment

• The National Comprehensive Cancer Network suggests clinical review, chest X-ray, and tumor markers monthly for year 1, every 2 months for year 2, every 4 months for year 3, then every 6 months to 5 years for patients on surveillance (Stage I) 6.
• The American Society of Clinical Oncology recommends clinical review, chest X-ray, and tumor markers every 2 months for year 1, every 3 months for year 2, then every 6 months to 5 years, then annually for post-chemotherapy patients 6.

Guidelines for Ordering Quantitative β‑hCG in Adult Males

Panel Composition and Ordering

• The NCCN guidelines recommend that serum quantitative β‑hCG be ordered as part of a mandatory three‑marker panel (including AFP and LDH) before any diagnostic or therapeutic intervention in males with suspected testicular masses or undergoing infertility work‑up. 9, 10
• The NCCN guidelines state that all three tumor markers should be requested simultaneously—serum AFP, quantitative β‑hCG, and LDH—prior to orchiectomy or any other intervention in patients with suspected germ‑cell tumors. 9, 10
• To obtain numeric results, clinicians must specify “quantitative β‑hCG” or “serum β‑hCG” on the order; this prevents receipt of only qualitative (positive/negative) reports. 10, 11
• Even when physical examination and scrotal ultrasound are normal, the NCCN advises ordering the three‑marker panel because normal marker levels do not exclude a testicular neoplasm. 9

Timing of Sample Collection

• Blood for the marker panel should be drawn before orchiectomy to establish baseline values that guide all subsequent treatment decisions. 9, 10
• The NCCN recommends repeating the full panel after orchiectomy to assess for residual disease, using the known β‑hCG half‑life of approximately 1.5–3 days to verify appropriate decline. 11
• When initial β‑hCG values are elevated, the NCCN advises repeat testing to confirm the elevation and to enable precise staging before initiating therapy. 10, 11

Interpretation Pitfalls

• Marijuana use can cause benign serum elevations of β‑hCG that do not indicate malignancy; clinicians should consider this potential confounder when interpreting results. 10, 11
• Heterophilic antibodies may generate false‑positive hCG results, particularly in assays that lack blocking agents; awareness of this limitation is essential to avoid misdiagnosis. 9

Clinical Indications for Ordering

• In males with an intratesticular mass identified on ultrasound, the NCCN recommends ordering the three‑marker panel immediately. 10, 11
• For infertility evaluation, the NCCN advises ordering the panel when ultrasound shows suspicious features such as a hypoechoic lesion, macrocalcification, or marked testicular atrophy. 10

Management Based on Marker Elevation

• In rare, medically unstable patients with life‑threatening metastatic disease and a testicular, retroperitoneal, or anterior mediastinal mass, markedly elevated β‑hCG and/or AFP may be considered sufficient for a germ‑cell tumor diagnosis, allowing prompt initiation of chemotherapy without awaiting tissue confirmation. 9